摘要
2019新型冠状病毒(2019 novel coronavirus,COVID-19)肺炎的治疗迫在眉睫,令人心焦的是,目前市场上还没有一种明确的药物可以预防或治疗。抗疟药氯喹已在临床使用70多年,安全性高。近期研究显示氯喹可以抑制多种病毒的活性,很有可能成为治疗2019新型冠状病毒肺炎的潜在药物。基于PubMed数据库,我们对近年氯喹抗病毒的研究做一总结,并探讨基于氯喹抗2019新型冠状病毒的可行性及其策略,以期为当前抗2019新型冠状病毒药物的研发或临床治疗2019新型冠状病毒肺炎的策略提供有益的帮助。
The treatment of 2019 novel coronavirus(COVID-19)pneumonia is imminent.It is very anxious that there is no marketed drug for prevention or treatment.Chloroquine is an antimalarial drug that has been safely used for more than 70 years.Recent studies have shown that chloroquine can inhibit the activity of a variety of viruses and is likely to become a potential drug for the COVID-19 Pneumonia.Herein we focused on the role of chloroquine in the study of multiple viral diseases basing on the literature from PubMed data base,with a view to help the current R&D of anti-COVID-19 drug and also the treatment of COVID-19 Pneumonia.
作者
陈晨
朱泽宇
彭伟嘉
杨扬
鲁俊锋
刘宇洁
皮荣标
CHEN Chen;ZHU Zeyu;PENG Weijia;YANG Yang;LU Junfeng;LIU Yujie;PI Rongbiao(School of Pharmaceutic Sciences,Sun Yat-sen University,Guangzhou 510006,China;Department of Clinic Medicine,Jilin Medical University,Changchun 132013,China;School of Medicine,Sun Yat-sen University,Guangzhou 510006,China;International Joint Laboratory<SYSU-PolyU HK>of Novel Anti-dementia Drugs of Guangdong,Guangzhou 510006,China)
出处
《药学研究》
CAS
2020年第2期63-73,共11页
Journal of Pharmaceutical Research